Dexamethasone - CAS 50-02-2
Category:
APIs
Product Name:
Dexamethasone
Catalog Number:
50-02-2
CAS Number:
50-02-2
Molecular Weight:
392.46
Molecular Formula:
C22H29FO5
Quality Standard:
BP/USP
COA:
Inquire
MSDS:
Inquire
Chemical Structure
CAS 50-02-2 Dexamethasone

Related Products


CAS 1880-61-1 17-Oxo Dexamethasone

17-Oxo Dexamethasone
(CAS: 1880-61-1)

CAS 37927-01-8 (-)-Dexamethasone acid

(-)-Dexamethasone acid
(CAS: 37927-01-8)

CAS 37927-01-8 Dexamethasone Sodium phosphate Impurity G ((-)-Dexamethasone Acid)

Dexamethasone Sodium phosphate Impurity
(CAS: 37927-01-8)

Dexamethasone impurity.

CAS 382-67-2 Desoximetasone

Desoximetasone
(CAS: 382-67-2)

Desoximetasone is a synthetic corticosteroid, a class of primarily synthetic steroids used as anti-inflammatory and anti-pruritic agents, which is used for the ...

CAS 382-67-2 Desoximetasone

Desoximetasone
(CAS: 382-67-2)

Desoximetasone is a medication belonging to the family of medications known as topical corticosteroids. It is used for the relief of various skin conditions, in...

CAS 382-67-2 Dexamethasone Impurity F

Dexamethasone Impurity F
(CAS: 382-67-2)

Dexamethasone impurity

CAS 887405-45-0 CHEMBRDG-BB 4002906

CHEMBRDG-BB 4002906
(CAS: 887405-45-0)

Reference Reading


1.Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial
Hye Jin Kim & Sung-Soo Yoon & Dong Soon Lee. Ann Hematol (2012) 91:249–256
The vincristine, adriamycin, and dexamethasone (VAD) combination regimen has been commonly used as an induction chemotherapy for those patients who are potential candidates for ASCT, but novel agents such as thalidomide, bortezomib, and lenalidomide are recently replacing VAD due to their increased efficacy. Thalidomide is an oral agent with immunomodulatory and antiangiogenic properties, and it has shown significant activity for patients with refractory multiple myeloma as a single agent, and thalidomide combined with dexamethasone has shown an increased response rate for patients with refractory or newly diagnosed multiple myeloma. Bortezomib is a selective and reversible proteasome inhibitor that inhibits the degradation of ubiquitinated target proteins. It has shown a high response rate for patients with relapsed or refractory multiple myeloma in SUMMIT and CREST trials. The addition of dexamethasone to bortezomib has been associated with an improved response without prohibitive toxicity. For newly diagnosed patients with multiple myeloma, bortezomib alone, and in combination with dexamethasone, has achieved 90% response rate or better including complete response (CR) + near CR rate of 20% in various trials [20]. A recent phase I/II study with bortezomib, thalidomide, and dexamethasone (VTD) reported remarkable efficacy in patients with advanced and refractory myeloma with a partial remission (PR) rate of 63% and a near CR rate of 22% .